Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use
Cysteamine prodrugs, pharmaceutical compositions comprising the cysteamine prodrugs, and methods of using cysteamine prodrugs and pharmaceutical compositions thereof for treating eye, kidney, liver, metabolic, and neurological disorders such as cystinosis, cystinuria, non-alcoholic steatohepatitis, Batten disease, Leigh syndrome, and Huntington's disease.
1. A compound according to Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X 1 is ethane-1,2-diyl;
W 1 is chosen from a substituent of Formula (I-a) or Formula (I-b); and
W 2 is chosen from hydrogen or the same substitutent as W 1 :
wherein
R 1 , R 2 , R 3 , and R 4 are independently chosen from hydrogen, C 1-6 alkyl, C 3-12 cycloalkyl, C 3-12 heterocycloalkyl, C 5-10 aryl, and C 5-10 heteroaryl; and
Y 1 is chosen from a bond and —O—.
2. The compound according to claim 1 , wherein W 1 is chosen from the substituent of Formula (I-a) or Formula (I-b), wherein R 1 , R 2 , R 3 , and R 4 are independently chosen from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, and benzyl; and Y 1 is chosen from a bond and —O—.
3. The compound according to claim 1 , wherein W 1 is chosen from the substituent of Formula (I-a), wherein R 1 is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, and benzyl; R 2 and R 3 are independently chosen from hydrogen and methyl; and Y 1 is a bond.
4. The compound according to claim 1 , wherein W 1 is chosen from the substituent of Formula (I-b), wherein R 4 is methyl.
5. The compound according to claim 1 , wherein W 2 is hydrogen.
6. The compound according to claim 1 , wherein W 1 and W 2 are the same and chosen from the substituent of Formula (I-a), wherein R 1 is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, and benzyl; R 2 and R 3 are independently chosen from hydrogen and methyl; and Y 1 is a bond.
7. The compound according to claim 1 , wherein W 1 and W 2 are the same and chosen from the substituent of Formula (I-b), wherein R 4 is methyl.
8. The compound according to claim 1 , wherein X 1 is ethane-1,2-diyl; and W 1 and W 2 are the same and chosen from the substituent of Formula (I-a) or Formula (I-b); wherein R 1 , R 2 , R 3 , and R 4 are independently chosen from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, and benzyl; and Y 1 is chosen from a bond and —O—.
9. The compound according to claim 1 , wherein X 1 is ethane-1,2-diyl; W 1 is chosen from the substituent of Formula (I-a) or Formula (I-b); and W 2 is hydrogen; wherein R 1 , R 2 , R 3 , and R 4 are independently chosen from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, and benzyl; and Y 1 is chosen from a bond and —O—.
10. The compound according to claim 1 , wherein the compound is chosen from the compounds of Formula (I-A-1), Formula (I-A-3), Formula (I-A-4), Formula (I-A-5), and Formula (I-A-6):
11. The compound according to claim 1 , wherein the compound is chosen from the compounds of Formula (I-B-1), Formula (I-B-3), Formula (I-B-4), Formula (I-B-5), Formula (I-B-6), Formula (I-B-19), Formula (I-B-21), Formula (I-B-22), Formula (I-B-23), and Formula (I-B-24):
12. The compound according to claim 1 , wherein the compound is chosen from the compounds of Formula (I-D-1) and Formula (I-D-3):
13. A pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a therapeutically effective amount of a compound selected from the compounds listed in claims 10 , 11 , and 12 .
14. The pharmaceutical composition according to claim 13 , wherein the composition is suitable for oral, inhalation, ophthalmic, or topical administration.
15. The pharmaceutical composition according to claim 13 , wherein the composition is suitable for sustained release formulation.
16. The pharmaceutical composition according to claim 13 , wherein the composition is suitable for controlled release formulation.